PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80009Doxycycline hyclate 100 MG ORAL tablets — Chartwell Rx LLC

Chartwell Rx LLC holds $76.1M across 576 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent 36F79720D0198. Competition previously drew 2 offers. Set-aside status: SBA. Recompete timing centers on the Jun 22, 2029 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Department of Health and Human Services (HHS)

Agency

Chartwell Rx LLC

Recipient

Jun 22, 2029

PoP end

$98.7M

Obligated

325412

NAICS

6505

PSC

SBA

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

SBA

Contract number75A50325F80009

Also listed as36F79720D0198-75A50325F80009

AgencyDepartment of Health and Human Services (HHS)

Awarding officeAspr/Orm-Sns

IncumbentChartwell Rx LLC

UEIER5UA9TYBGH4

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0198

Place of performanceCONGERS, NY

PoP end (current)Jun 22, 2029

Obligated$98.7M

DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS is a federal SBA award for Department of Health and Human Services (HHS) held by Chartwell Rx LLC. Estimated value $98.7M ($98.7M obligated). Current period of performance ends Jun 22, 2029. Last award drew 2 bidders. Place of performance: CONGERS, NY.

Recompete timing

Public

● Expiring in 996 days

Current PoP ends Jun 22, 2029 (996 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Dec 22, 2027.

Bonuses end Sept 30

Want the durability read on 75A50325F80009? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Chartwell Rx LLC — $76.1M obligated across 576 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($76.1M) · all agencies

Department of Health and Human Services (HHS)$74.1M · 97%Department of Defense (DOD)$1.9M · 2%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D026F0099

8511936905!OTHER MEDICAL

$649K

Apr 19, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50325F80009?

75A50325F80009 (Doxycycline hyclate 100 MG ORAL tablets) is a Aspr/Orm-Sns award with an estimated value of $98.7M, currently held by Chartwell Rx LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325F80009?

Aspr/Orm-Sns awarded 75A50325F80009 to Chartwell Rx LLC.

Who is the incumbent on 75A50325F80009?

Chartwell Rx LLC is the incumbent with $76.1M across 576 related awards in SCOUT’s public footprint. The current period of performance ends Jun 22, 2029.

When does Chartwell Rx LLC’s 75A50325F80009 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 22, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50325F80009? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Sep 10, 2026 · refreshed monthlyLatest procurement action Dec 22, 2025